

Review

Bacterial Amyloids: The Link between Bacterial Infections and Autoimmunity

Lauren Nicastro¹ and Çağla Tükel^{1,*}

Molecular mimicry is a common mechanism used by many bacteria to evade immune responses. In recent years, it has become evident that bacteria also decorate the extracellular matrix (ECM) of their biofilms with molecules that resemble those of the host. These molecules include amyloids and other proteins, polysaccharides, and extracellular DNA. Bacterial amyloids, like curli, and extracellular DNA are found in the biofilms of many species. Recent work demonstrated that curli and DNA form unique molecular structures that are recognized by the immune system, causing activation of autoimmune pathways. Although a variety of mechanisms have been suggested as the means by which infections initiate and/or exacerbate autoimmune diseases, the mechanism remains unknown. In this article, we discuss recent work on biofilms that highlight the role of amyloids as a carrier for DNA and potentiator of autoimmune responses, and we propose a novel link between bacterial infections and autoimmune diseases.

Infections and Autoimmune Diseases

Chronic autoimmune diseases occur when the immune system recognizes self-antigens as foreign, leading to inflammation and destruction of specific tissues and organs. Autoimmunity was first recognized by a famous physician, Paul Ehrlich, in the early 1900s. He realized that the powerful effector mechanisms used in host defense could, if turned against the host, cause severe tissue damage; Ehrlich termed this horror 'autotoxicus'. To protect itself from an autoimmune response, the body uses a technique called self-tolerance in which T cells go through a negative selection process. Not all self-reactive T cells are removed, however, and the remaining self-reactive T cells must be regulated to avoid an autoimmune response. Dysregulation of these T cells in the periphery can lead to autoimmune responses throughout the body, the reaction first described by Ehrlich.

There is evidence that infectious agents can trigger gut or systemic autoimmune diseases. However, opposing evidence, primarily from animal models of autoimmunity, suggests that many autoimmune disorders occur through internal dysregulation of the immune system without the participation of infectious agents. It is now accepted that susceptibility to autoimmune diseases is multifactorial and that the interaction between genetic and environmental factors underlies disease progression. Different genetic factors are associated with susceptibility to autoimmune disease, and various environmental factors feed into breaking tolerance to self-antigens in the susceptible host. Infections are considered to be one of these environmental factors. How infections contribute to the disease onset or flares of many autoimmune diseases remains a mystery, however. In this review we discuss how amyloid-expressing enteric bacteria drive autoimmune reactions during infections. Amyloids and DNA that potentially trigger autoimmune responses are expressed by many important human pathogens, such as *Escherichia coli*, *Borrelia burgdorferi*, *Salmonella enterica* serovar Typhimurium, *Mycobacterium tuberculosis*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus*. It is important to note that the bacteria discussed here, with the exception of curli-producing *E. coli* and *S. Typhimurium*, as well as phenol soluble modulins producing *S. aureus*, have not been shown to produce amyloid/DNA complexes. Many of these bacteria produce amyloids and extracellular DNA in their biofilms *in vitro*. However, the production of amyloids as part of a biofilm during human infection, and their interactions with DNA leading to autoimmunity, needs further investigation.

Autoimmune Sequelae Following Bacterial Infections

There are many examples of diseases in which bacterial infections initiate or exacerbate autoimmune responses (Figure 1). One of the well-described autoimmune conditions that develop in

Highlights

Autoimmune responses are generated during many bacterial infections. Most bacteria that cause autoimmune sequelae post-infection produce amyloid proteins.

Amyloids are detected in biofilms produced by many bacterial species.

The incorporation of amyloid and DNA into the biofilm ECM enhances biofilm stability.

Amyloid/DNA complexes are dominant molecular signatures that the immune system recognizes.

Systemic exposure to amyloid/DNA complexes leads to an autoimmune response via Toll-like receptor (TLR)2 and TLR9.

Biofilm-associated infections have the potential to generate autoimmunity via presentation of amyloid/DNA complexes to the immune system.

¹Department of Microbiology and Immunology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA


*Correspondence: ctukel@temple.edu



response to an infection is reactive arthritis (ReA), also known as postinfectious arthritis or ankylosing spondylitis. ReA is a painful form of inflammatory arthritis caused after gastrointestinal infections with enteric pathogens such as *Salmonella*, *Shigella*, *Yersinia*, or *Campylobacter* or after genital infection with *Chlamydia trachomatis* [1]. ReA usually starts 1–4 weeks postinfection. ReA affects the joints, and many patients also develop eye inflammation (conjunctivitis) and urinary problems (urethritis). ReA affects approximately 5% of patients following gastrointestinal infections, and some patients remain symptomatic for 5 years or longer. ReA has traditionally been thought of as a ‘sterile’ arthritis because antibiotic treatment in individuals with ReA is ineffective [2,3] and cultures of joint fluids yield no growth of organisms. Recent evidence suggests, however, that *Chlamydia* species can become persistent in joint and synovial tissue [4,5] of patients with ReA, and immunocytochemical staining and mass spectrometry has demonstrated the presence of enteric bacterial products in the synovial fluid, further implicating microorganisms in the inflammatory process [6–8].

Genetic variations and differences in etiology make treatment of ReA difficult. For example, the histocompatibility leukocyte antigen (HLA)-B27 genotype is a risk factor for ReA, and over two-thirds of the patients with ReA carry the HLA-B27 genotype. Those patients negative for HLA-B27 are frequently positive for cross-reacting antigens such as HLA-B7, HLA-B22, HLA-B40, or HLA-B42 [9]. It has been suggested that the bacteria express antigens that react with HLA-B27, but it is still unclear why HLA-B27 predisposes individuals to ReA.

In addition to ReA, there are other examples of arthritis likely induced by bacterial infection that are not associated with HLA-B27. Poststreptococcal arthritis is a poorly understood clinical syndrome; it is not clear whether it is a separate entity or a condition that presents with rheumatic fever. Group A streptococci colonize the throat or skin and are responsible for various infections and



Trends in Microbiology

Figure 1. Human Infections Followed by Autoimmune Sequelae.

Shown are human infections with their associated causative bacteria. Each line links the infection to the appropriate site of infection on the body. Amyloid-producing bacteria are marked in red. Abbreviation: PANDAS, pediatric autoimmune neuropsychiatric disorders associated with streptococci.

poststreptococcal immune sequelae. These bacteria are the most common cause of pharyngitis in school-aged children. Rheumatic fever or rheumatic heart disease is an important autoimmune sequela that follows pharyngitis. Molecular mimicry by M-protein and the production of cross-reactive antibodies are important for the pathogenesis. Antibodies that recognize the M-protein and the N-acetyl- β -D-glucosamine of *Streptococcus pyogenes* cross-react with myosin, leading to heart damage [10,11]. Some of the rheumatic heart disease patients also experience arthritis postinfection. However, the mechanisms that trigger arthritis are not known.

Recently, streptococcal carriage has been proposed to have a role in a human skin autoimmune disease, psoriasis. An interesting connection was discovered when researchers found that tonsillectomy provided relief of symptoms in psoriasis patients [12]. Streptococcal biofilms that cause chronic infections of the tonsils are thought to exacerbate psoriatic symptoms. This was supported by data showing that patients with moderate to severe chronic plaque psoriasis have shown improvement in skin lesions upon long-term penicillin treatment [12,13].

The pediatric autoimmune neuropsychiatric disorders associated with streptococci, or PANDAS, are a neurological response seen in children after they have been treated for a group A streptococcal infection (strep throat) [14]. Patients present with an obsessive compulsive or tic disorder and express antineuronal antibodies against dopamine receptors [14]. This condition is one of very few examples of an autoimmune reaction within the brain, most often thought of as an immune privileged area of the body. This provides evidence for an axis of interaction between the peripheral streptococcal infection and the neurological response.

Another example of autoimmunity induced by bacterial infections is Lyme disease. Lyme disease is a tick-borne disease caused mainly by the *B. burgdorferi* bacterium, though other *Borrelia* species have been found to cause the disease in rare cases. If untreated, *Borrelia* species spread throughout the body and cause arthritis and nervous system problems as well as pain and fatigue. Although quite controversial, biofilms of *Borrelia* were detected in a recent study and proposed to be responsible for the persistent infection and continuation of disease symptoms [15]. Intriguingly, many Lyme disease symptoms overlap with those of systemic lupus erythematosus (SLE), a chronic human autoimmune disease. Furthermore, autoantibodies detected in sera from Lyme disease patients are the same as those observed in SLE patients. For example, Lyme patients, like SLE patients, test positive for anti-nuclear antibodies (ANAs) [16,17]. Molecular mimicry of γ -enolase by *Borrelia* enolase has been suggested to drive the autoimmune response and more chronic symptoms [18].

Mysteriously, most individuals positive for ANAs do not have an autoimmune disease. This brings up the question of whether the generation of autoantibodies postinfection is a common response to bacterial infection. Consistent with this idea, anti-double-stranded DNA antibodies and antibodies to other autoantigens are seen in patients who have had lung infections caused by *P. aeruginosa*, biliary tract infections caused by enteric bacteria, and bacterial prostatitis caused by *E. coli* [19–21]. The most controversial infection that has been proposed to be an infection-initiated autoimmune disease is tuberculosis [22].

M. tuberculosis infections cause granuloma formation, and patients have a depressed immune response [23]. Further, 40% of tuberculosis patients present with autoantibodies normally associated with SLE and Wegener's granulomatosis [22]. Additionally, inflammatory arthritis occurs in some patients even without detectable bacteria within the joint space. Tuberculosis shares symptoms with multiple autoimmune diseases, including irritable bowel disease, Crohn's disease, ankylosing spondylitis, and sarcoidosis to name a few [22,24,25]. Sarcoidosis diagnoses often mirror those of tuberculosis, the only difference being a lack of *Mycobacterium* presence in the tissues [22,25]. The similarities between these disease states indicate that similar host molecules are at play in these conditions.

Intriguingly, of all the bacteria implicated in the diseases described above, most have been shown to express amyloids, a type of molecule that the immune system recognizes as a conserved molecular pattern (Figure 1). Though the production of amyloids during human infection remains speculative, increasing evidence suggests that amyloids may be the link between infections and autoimmunity. Regardless of their amino acid sequence, amyloids are characterized by their conserved β -sheet fibrillar structure [26]. It is this conserved structure that is recognized by the innate immune receptors such as the Toll-like receptor (TLR)2/TLR1 heterocomplex and Nod-like receptor protein 3 (NLRP3) [27,28]. Bacteria produce amyloids as part of their biofilm, introducing a common molecular pattern for host recognition. In most cases, it remains unclear whether bacterial amyloids are expressed during the infections that trigger autoimmune reactions.

Bacterial Amyloids: Survival Strategy and Molecular Mimicry

In a biofilm, a group of bacteria are encapsulated in a 3D, self-produced ECM that adheres to abiotic or biotic surfaces [29,30]. Bacteria produce biofilms to protect the population from environmental insults, including antimicrobials, physical shear stress, or the immune response. Intriguingly, the biofilm ECM makes up 85% of the biofilm mass. Bacterial amyloid proteins that possess a conserved cross β -sheet structure serve as a strong scaffold for the ECM [31,32]. Amyloids are highly resistant to chemical, proteolytic, and enzymatic degradation, and therefore provide a strong scaffold for the community and act almost like a shield under stress [33,34]. Moreover, amyloids are expressed also by humans [35–37]; therefore, bacteria may use these molecules to hide the bacterial community from the immune system.

Depending on the habitat, between 5% and 40% of species isolated from environmental biofilms produce amyloids, demonstrating the widespread distribution of this extracellular structure [38]. Curli fibers are amyloids produced in the biofilms of enteric bacteria in the environment as well as during infections [39]. Curli fibers have high structural and functional similarity to human amyloids [33,39–41]. Although expression, function, and immune activation by *E. coli* and *Salmonella* curli species are well characterized, *in vivo* expression of curli by clinical enteric strains has yet to be described. Phylogenetic analysis suggests that the curli assembly machinery is widespread, as homologs of the *csg* genes, which encode curli and are responsible for their biosynthesis and secretion, are found within four phyla – Bacteroidetes, Proteobacter, Firmicutes, and Thermodesulfobacteria – as well as in nine different classes of sequenced bacteria [42]. Consistent with these findings, many pathogenic bacteria associated with autoimmune sequelae postinfection produce amyloid proteins. Staphylococci produce phenol-soluble modulins and Bap amyloids; *Streptococcus mutans* produces amyloidogenic P1, WapA, and SMU_63c; *Pseudomonas* sp. produces FapC amyloid; and *B. burgdorferi* produces OspA amyloid [43–49]. As *S. mutans* produces amyloid, it is thought that other *Streptococcus* sp. may be producing amyloids as well. Intriguingly, *M. tuberculosis* has been reported to express a curli-like amyloid during human infection [48]; however, not much is known about this protein.

OspA protein is an amyloid protein and a major virulence factor expressed by *B. burgdorferi*, the pathogen that causes Lyme disease. The importance of this protein during infection is highlighted by studies showing anti-OspA treatment is protective against infection in mice [50]. Not only is this protein necessary for infection, but it is also used by *Borrelia* sp. as a molecular mimic for adhesion molecule LFA-1 α [51]. LFA-1 α is a partial agonist of antibodies against OspA, and it exacerbates autoimmune symptoms [52]. Finally, sequence similarity between *B. burgdorferi* OspA and *S. pyogenes* M5 proteins has been reported [53]. These findings suggest that bacteria produce molecules similar to host molecules to mitigate the immune onslaught.

In the bigger picture of infections involving biofilms, the National Institutes of Health reported that, among acute and chronic microbial infections, 65% and 80%, respectively, are associated with biofilm formation [54]. Infections associated with biofilms include urinary tract infections, middle-ear infections, bone and joint infections, dental caries, periodontitis, endocarditis, chronic tonsillitis, cystic fibrosis, bacterial prostatitis, biliary tract infections, and infections of persistent indwelling devices

such as heart valves and joint prostheses. Many urinary tract infections and bloodstream infections are a result of biofilms associated with indwelling medical devices [55–57]. Among the long list of bacteria that cause biofilm-associated infections, amyloid-producing bacteria make up a significant number (Figure 2), and the number of amyloid-producing bacteria may be underestimated. Amyloids do not share a conserved amino acid sequence, therefore it is hard to determine if a bacterial species produces an amyloid by analysis of gene sequences. One common method to screen for amyloid production by bacteria is to supplement growth media with Congo Red, an amyloid indicator dye. Amyloid production is indicated by a red colony phenotype. Congo Red, however, has the potential to stain other polysaccharide components of the biofilm and therefore amyloid production can be confirmed with the addition of Coomassie brilliant blue to the plates, or with the use of another amyloid-specific dye, Thioflavin T [38,58–60]. It must also be noted that, for most of the bacterial species that are amyloid producers, the presence of amyloid during infection has not been definitely demonstrated. For instance, although *S. aureus* produces phenol-soluble modulins or Bap in biofilms generated *in vitro* in laboratory conditions [49,61,62], it is not known whether staphylococci produce these amyloids during infections or whether the repertoire of amyloids influences the type of immune response.

Enteric Bacterial Biofilms: Curli, Extracellular DNA, and Autoimmunity

Although the bacteria produce amyloids as a way to hide from the insults of the immune cells, the immune system in turn recognizes the amyloids as conserved molecular signatures to detect bacterial activity. For instance, curli is recognized by the TLR2/TLR1 complex and the NLRP3 inflammasome [27,28,63,64]. It is important to note that Toll-like receptors also recognize human amyloids, including β -amyloid, which is present in plaques in the brains of patients with Alzheimer's disease, and serum amyloid A (SAA). Studies suggest that the TLR2/TLR1 heterocomplex is a major innate immune

Infection		Implanted device infection	
Otitis media	Nontypeable <i>Haemophilus influenzae</i> , <i>Moraxella catarrhalis</i> , <i>Chlamydia pneumoniae</i> , <i>Streptococcus pneumoniae</i> , <i>Streptococcus pyogenes</i>	Sutures	Staphylococci
Dental caries	<i>Streptococcus</i> sp.	Ventilator assoc. pneumonia	<i>Klebsiella</i> sp., <i>Pseudomonas aeruginosa</i> , <i>Staphylococcus aureus</i>
Periodontitis	Gram-negative anaerobic oral bacteria	Mechanical heart valves	Staphylococci (<i>epidermidis</i> and <i>aureus</i>), Gram-negative rods, diphtheroids, enterococci
Chronic tonsillitis	Streptococci	Arteriovenous shunts	Staphylococci
Endocarditis	Viridans streptococci, <i>Streptococcus bovis</i> , Coagulase-negative staphylococci, <i>Staphylococcus aureus</i> , enterococci	Endovascular catheter	Staphylococci
Necrotizing fasciitis	Group A streptococci	Peritoneal dialysis/peritonitis	<i>Escherichia coli</i> , <i>Klebsiella</i> sp., <i>Proteus</i> sp., <i>Enterococcus faecalis</i> , <i>Pseudomonas</i> sp., etc.
Osteomyelitis	Staphylococci, <i>Pseudomonas</i> sp., <i>Escherichia coli</i> , <i>Serratia marcescens</i>	Cerebral spinal fluid shunt	Staphylococci
Biliary tract infections	Enteric bacteria (<i>E. coli</i> , <i>Klebsiella</i> , <i>Pseudomonas</i> , <i>Enterobacter</i>) enterococci, streptococci, <i>Bacteroides</i> , <i>Clostridium</i>	Urinary catheter	<i>Escherichia coli</i> , <i>Proteus mirabilis</i> , enterococci, <i>Pseudomonas aeruginosa</i>
Infectious kidney stones	Gram-negative rods		
Bacterial prostatitis	<i>Escherichia coli</i> , <i>Proteus mirabilis</i> , <i>Klebsiella</i> , <i>Enterobacter</i> , <i>Pseudomonas aeruginosa</i>		
Septic arthritis	Staphylococci, <i>Pseudomonas</i> sp., <i>Haemophilus influenzae</i> (children), <i>Streptococcus agalactiae</i> (children)		
Lyme disease	<i>Borrelia</i> sp.		
Rheumatoid arthritis	<i>Proteus mirabilis</i>		

Trends in Microbiology

Figure 2. Biofilm-Related Infections in Humans.

Infections of native body tissue are shown in the left table, while bodily infections associated with implanted devices are shown in the table on the right. Amyloid-producing bacteria are marked in red text.

receptor that recognizes the fibrillar β -sheet structure of bacterial amyloid curli, human β -amyloid, and human SAA. The NLRP3 inflammasome also recognizes β -amyloid and SAA [64–68]. Amyloids produced by other bacteria are likely also bound by the TLR2/TLR1 complex and NLRP3 inflammasome due to their common fibrillar β -sheet structure. Thus, amyloids may mimic host molecules to hide from the immune system. In return, the immune system recognizes these molecules regardless of their origin, which may initiate the autoimmune responses.

In addition to amyloids, carbohydrates and extracellular DNA are major constituents of the ECM of biofilms [32,39,69]. For example, cellulose produced by enteric bacteria is integrated into the biofilm ECM, providing additional structural support and protection. A recent study demonstrated that curli and bacterial DNA form complexes in enteric biofilms that are highly proinflammatory compared with curli alone or DNA alone [70]. In fact, curli/DNA complexes activate multiple innate immune receptors in various compartments of an immune cell: first, curli fibers activate the TLR2/TLR1 heterocomplex on the membrane [28,63,64], and then internalization of this complex brings curli/DNA into the endosome to activate the DNA receptor TLR9 [71], followed by cytosolic escape of fibrillar curli, which activates NLRP3 [27]. Structural analysis suggests that the curli fibers organize DNA with an inter-DNA spacing that promotes effective, multivalent TLR9 binding and activation [71].

Lipopolysaccharide (LPS) and flagellin are thought to be the dominant molecular signatures of enteric bacteria recognized by the immune system. However, recent studies show that, in the case of a biofilm, curli/DNA complexes serve as the dominant molecular signature that triggers the autoimmune response [70]. Since bacteria decorate the ECM with molecules that resemble the host, it is not surprising that bacterial biofilms that harbor curli and DNA elicit an autoimmune response. In murine models, infection with either commensal *E. coli* or pathogenic *S. enterica* serovar Typhimurium leads to elevated levels of antibodies to double-stranded DNA and chromatin as well as positive ANA results, and these responses require expression of curli by the bacteria [70]. Injection of purified curli/DNA complexes triggers similar responses in mice that are dependent on the activation of TLR2 and TLR9. Thus, amyloid curli fibers serve as a carrier for DNA and the generation of subsequent DNA-related responses [71].

The elevation of autoantibodies induced by curli/DNA complexes occurs both in lupus-prone and in wild-type mice [70]. Therefore, it is possible that the autoimmunity is triggered by biofilm-related infections, even in individuals without an autoimmune disease, although this autoimmunity may be resolved over time by the competent immune system. If, however, the individual is already predisposed to an autoimmune disease by genetic factors, and there is exposure to the biofilm for a long period of time, biofilm-related infections may contribute to disease progression or flares. We speculate that an autoimmune response driven by curli/DNA complexes contributes to the development of ReA following enteric infections. It is possible that during a gastroenteritis outbreak caused by enteric bacteria, individuals with the HLA-B27 genotype will develop an exacerbated immune response and ReA, whereas those with other HLA genotypes experience an autoimmune response that is moderate or transient. Although these connections are speculative, they warrant further investigation.

SLE

Generation of autoantibodies, including anti-double-stranded DNA antibodies, and the type I interferon response, are hallmarks of the human autoimmune disease SLE [70]. SLE is considered a prototypical autoimmune disease; 80% of SLE patients develop joint and muscle pain, skin rashes, fatigue, and a general feeling of being unwell. SLE is often mistaken for other diseases. ANA test is used to confirm the presence of autoantibodies to aid in diagnosis [72]. Intriguingly, patients who eventually develop SLE show positivity for anti-double-stranded DNA and antichromatin years before the diagnosis [73].

Infections are the most common causes of hospitalization and mortality in SLE patients. The frequencies of infections in SLE patients, such as pneumonia, sepsis, skin infections, and urinary tract

infections, are similar to those of the general population and are caused by both Gram-positive and Gram-negative bacteria [74]. However, infections (both viral and bacterial) trigger flares in SLE patients. During a lupus flare, the most common complaints are of flu-like symptoms (with or without fever), fatigue, and muscle and joint pains. However, continual flare-ups negatively affect various organs, including kidneys and lungs, and can eventually lead to organ failure and death [75].

Genome-wide association studies suggest an involvement of Toll-like receptors in the pathogenesis of SLE [76]. It is well established that DNA triggers autoimmune responses and contributes to the pathogenesis of SLE via the activation of TLR9 [77]. Although polymorphisms of *TLR2* have no correlation with predisposition to SLE, peripheral blood mononuclear cells (PBMCs) from lupus patients express higher levels of TLR2 than PBMCs from healthy controls [76], suggesting that SLE patients may react more strongly to TLR2 ligands than do healthy individuals.

SLE patients have elevated levels of LPS in systemic circulation, suggesting that the immune systems of these patients are frequently exposed to bacterial products [78]. Consistent with this, infection with *S. Typhimurium* or *E. coli* causes bacteremia, sepsis, or soft-tissue infections in SLE patients instead of the gastroenteritis and urinary tract infections common in otherwise healthy individuals. This shows how the altered immune system of these patients can influence the location where bacteria establish an infection. The fact that curli/DNA complexes from enteric biofilms, as well as several other infections by amyloid-producing bacteria, lead to positive ANA results suggests that there may be a link between the infections and autoimmunity.

Biofilms on Implanted Devices and Autoimmunity

Bacterial biofilms on implanted devices are difficult to treat, often requiring additional surgery or implant removal. Many bacteria that colonize implanted devices have the capacity to produce amyloids (Figure 2). There have been recent reports of patients who have undergone transvaginal mesh surgeries or hernia surgeries who have developed autoimmune diseases, including SLE, following surgery. It has been speculated that biofilms associated with the mesh break tolerance and trigger autoimmunity in these patients [79–82]. Consistent with this, recent work showed the presence of multiple species in biofilms on implanted mesh [83,84]. The connection between implants colonized with biofilms and autoimmune disease remains controversial, as some studies have shown no direct correlation between infected mesh implants and autoimmune disease onset. More mechanistic studies, as well as epidemiological studies, are needed to determine the complex immune reactions to biofilms on implanted devices in the future.

Concluding Remarks

Bacteria use biofilms as a hideout from the immune system to establish successful infections. Independent studies show that resolution of many infections are complicated by autoimmune sequelae for unknown reasons. Recent evidence showed that the molecules used by bacteria to decorate the ECM of the biofilms, for example, amyloid/DNA complexes, generate autoimmune responses during infections in animal models. It is thought that while biofilm-associated infections trigger a transient autoimmune response by bacterial amyloid/DNA complexes in healthy individuals, this response may be sustained and detrimental in individuals genetically predisposed to an autoimmune disease. However, at this point, the role of biofilm-associated infections as a trigger and modulator for human autoimmune diseases remains to be formally proven (see Outstanding Questions). Epidemiological studies that delve into the clinical history of patients and consider biofilm-associated infections or possible exposure to bacterial amyloids as a risk factor to develop autoimmune diseases are needed. More importantly, new practices to ensure the eradication of biofilms are needed to prevent the chronic exposure to biofilms. This will prevent the long-term exposure of the immune system to the biofilm products such as amyloid/DNA complexes that are capable of breaking immune tolerance.

Outstanding Questions

Are bacterial biofilms responsible for autoimmune sequelae postinfection?

Do biofilm-associated bacterial infections accelerate autoimmune disease onset and contribute to flares?

Do both Gram-negative and Gram-positive bacterial amyloids complex with DNA and trigger autoimmune reactions?

Are bacterial amyloid-like proteins expressed during many bacterial infections?

Do amyloids carry bacterial molecules other than DNA that can trigger autoimmunity?

References

- Carter, J.D. and Hudson, A.P. (2009) Reactive arthritis: clinical aspects and medical management. *Rheum. Dis. Clin. N. Am.* 35, 21–44
- Carter, J.D. et al. (2010) Combination antibiotics as a treatment for chronic *Chlamydia*-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. *Arthritis Rheum.* 62, 1298–1307
- Kvien, T.K. et al. (2004) Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. *Ann. Rheum. Dis.* 63, 1113–1119
- Carter, J.D. and Hudson, A.P. (2010) The evolving story of *Chlamydia*-induced reactive arthritis. *Curr. Opin. Rheumatol.* 22, 424–430
- Gerard, H.C. et al. (1998) Synovial *Chlamydia trachomatis* in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. *J. Rheumatol.* 25, 734–742
- Nikkari, S. et al. (1992) *Yersinia*-triggered reactive arthritis. Use of polymerase chain reaction and immunocytochemical staining in the detection of bacterial components from synovial specimens. *Arthritis Rheum.* 35, 682–687
- Nikkari, S. et al. (1999) *Salmonella*-triggered reactive arthritis: use of polymerase chain reaction, immunocytochemical staining, and gas chromatography-mass spectrometry in the detection of bacterial components from synovial fluid. *Arthritis Rheum.* 42, 84–89
- Sibilia, J. and Limbach, F.X. (2002) Reactive arthritis or chronic infectious arthritis? *Ann. Rheum. Dis.* 61, 580–587
- Nasution, A.R. et al. (1997) HLA-B27 subtypes positively and negatively associated with spondyloarthropathy. *J. Rheumatol.* 24, 1111–1114
- Cunningham, M.W. (2012) *Streptococcus* and rheumatic fever. *Curr. Opin. Rheumatol.* 24, 408–416
- Cunningham, M.W. et al. (1989) Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SER-LYS-GLN in M protein. *J. Immunol.* 143, 2677–2683
- Allen, H.B. et al. (2018) Psoriasis, chronic tonsillitis, and biofilms: Tonsillar pathologic findings supporting a microbial hypothesis. *Ear Nose Throat J.* 97, 79–82
- Saxena, V.N. and Dogra, J. (2005) Long-term use of penicillin for the treatment of chronic plaque psoriasis. *Eur. J. Dermatol.* 15, 359–362
- Cunningham, M.W. (2016) Post-streptococcal autoimmune sequelae: rheumatic fever and beyond. In *Streptococcus pyogenes: Basic Biology to Clinical Manifestations [Internet]*, J.J. Ferretti et al., eds. (Oklahoma City (OK): University of Oklahoma Health Sciences Center), Available from: <https://www.ncbi.nlm.nih.gov/books/NBK333434/>
- Sapi, E. et al. (2016) Evidence of *in vivo* existence of *Borrelia* biofilm in borrelial lymphocytomas. *Eur. J. Microbiol. Immunol.* 6, 9–24
- Federlin, K. and Becker, H. (1989) *Borrelia* infection and systemic lupus erythematosus. *Immun. Infekt.* 17, 195–198
- Singh, S.K. and Girschick, H.J. (2004) Lyme borreliosis: from infection to autoimmunity. *Clin. Microbiol. Infect.* 10, 598–614
- Maccallini, P. et al. (2018) Autoimmunity against a glycolytic enzyme as a possible cause for persistent symptoms in Lyme disease. *Med. Hypoth.* 110, 1–8
- Carter, C.J. (2011) Pathogen and autoantigen homologous regions within the cystic fibrosis transmembrane conductance regulator (CFTR) protein suggest an autoimmune treatable component of cystic fibrosis. *FEMS Immunol. Med. Microbiol.* 62, 197–214
- Gershwin, M.E. and Mackay, I.R. (2008) The causes of primary biliary cirrhosis: Convenient and inconvenient truths. *Hepatology* 47, 737–745
- Quick, M.L. et al. (2013) Th1-Th17 cells contribute to the development of uropathogenic *Escherichia coli*-induced chronic pelvic pain. *PLoS One* 8, e60987
- Elkington, P. et al. (2016) Tuberculosis: an infection-initiated autoimmune disease? *Trends Immunol.* 37, 815–818
- Pagan, A.J. and Ramakrishnan, L. (2014) Immunity and immunopathology in the tuberculous granuloma. *Cold Spring Harb. Perspect. Med.* 5, a018499
- Chodiseti, S.B. et al. (2012) Potential T cell epitopes of *Mycobacterium tuberculosis* that can instigate molecular mimicry against host: implications in autoimmune pathogenesis. *BMC Immunol.* 13, 13
- Maertzdorf, J. et al. (2012) Common patterns and disease-related signatures in tuberculosis and sarcoidosis. *Proc. Natl. Acad. Sci. U. S. A.* 109, 7853–7858
- Toyama, B.H. and Weissman, J.S. (2011) Amyloid structure: conformational diversity and consequences. *Annu. Rev. Biochem.* 80, 557–585
- Rapsinski, G.J. et al. (2015) Toll-like receptor 2 and NLRP3 cooperate to recognize a functional bacterial amyloid, curli. *Infect. Immun.* 83, 693–701
- Tukel, C. et al. (2010) Toll-like receptors 1 and 2 cooperatively mediate immune responses to curli, a common amyloid from enterobacterial biofilms. *Cell. Microbiol.* 12, 1495–1505
- Costerton, J.W. (1999) Introduction to biofilm. *Int. J. Antimicrob. Agents* 11, 217–221, discussion 237–219.
- Costerton, J.W. et al. (1995) Microbial biofilms. *Annu. Rev. Microbiol.* 49, 711–745
- Hung, C. et al. (2014) *Escherichia coli* biofilms have an organized and complex extracellular matrix structure. *mBio* 4, e00645-00613
- McCrate, O.A. et al. (2013) Sum of the parts: composition and architecture of the bacterial extracellular matrix. *J. Mol. Biol.* 425, 4286–4294
- Hufnagel, D.A. et al. (2013) Disease to dirt: the biology of microbial amyloids. *PLoS Pathog.* 9, e1003740
- Collinson, S.K. et al. (1991) Purification and characterization of thin, aggregative fimbriae from *Salmonella enteritidis*. *J. Bacteriol.* 173, 4773–4781
- Knowles, T.P. et al. (2014) The amyloid state and its association with protein misfolding diseases. *Nat. Rev. Mol. Cell Biol.* 15, 384–396
- Westermarck, G.T. et al. (1999) Staining methods for identification of amyloid in tissue. *Methods Enzymol.* 309, 3–25
- Maury, C.P. (2009) The emerging concept of functional amyloid. *J. Intern. Med.* 265, 329–334
- Larsen, P. et al. (2007) Amyloid adhesins are abundant in natural biofilms. *Environ. Microbiol.* 9, 3077–3090
- Tursi, S.A. and Tukel, C. (2018) Curli-containing enteric biofilms inside and out: matrix composition,

- immune recognition, and disease implications. *Microbiol. Mol. Biol. Rev.* 82, e00028-18
40. Barnhart, M.M. and Chapman, M.R. (2006) Curli biogenesis and function. *Annu. Rev. Microbiol.* 60, 131–147
 41. Chapman, M.R. et al. (2002) Role of *Escherichia coli* curli operons in directing amyloid fiber formation. *Science* 295, 851–855
 42. Dueholm, M.S. et al. (2012) Curli functional amyloid systems are phylogenetically widespread and display large diversity in operon and protein structure. *PLoS One* 7, e51274
 43. Mehlin, C. et al. (1999) An inflammatory polypeptide complex from *Staphylococcus epidermidis*: isolation and characterization. *J. Exp. Med.* 189, 907–918
 44. Lasa, I. and Penades, J.R. (2006) Bap: a family of surface proteins involved in biofilm formation. *Res. Microbiol.* 157, 99–107
 45. Besingi, R.N. et al. (2017) Functional amyloids in *Streptococcus mutans*, their use as targets of biofilm inhibition and initial characterization of SMU_63c. *Microbiology* 163, 488–501
 46. Dueholm, M.S. et al. (2010) Functional amyloid in *Pseudomonas*. *Mol. Microbiol.* 77, 1009–1020
 47. Ohnishi, S. et al. (2001) The roles of turn formation and cross-strand interactions in fibrillization of peptides derived from the OspA single-layer beta-sheet. *Protein Sci.* 10, 2083–2092
 48. Alteri, C.J. et al. (2007) *Mycobacterium tuberculosis* produces pili during human infection. *Proc. Natl. Acad. Sci. U. S. A.* 104, 5145–5150
 49. Schwartz, K. et al. (2012) Functional amyloids composed of phenol soluble modulins stabilize *Staphylococcus aureus* biofilms. *PLoS Pathog.* 8, e1002744
 50. Wang, Y. et al. (2019) Anti-OspA DNA-encoded monoclonal antibody prevents transmission of spirochetes in tick challenge providing sterilizing immunity in mice. *J. Infect. Dis.* 219, 1146–1150
 51. Pancewicz, S.A. et al. (2007) Immunopathology of Lyme arthritis. *Pol. Merkur. Lekarski* 23, 141–144
 52. Trollmo, C. et al. (2001) Molecular mimicry in Lyme arthritis demonstrated at the single cell level: LFA-1 alpha L is a partial agonist for outer surface protein A-reactive T cells. *J. Immunol.* 166, 5286–5291
 53. Raveche, E.S. et al. (2005) Evidence of *Borrelia* autoimmunity-induced component of Lyme carditis and arthritis. *J. Clin. Microbiol.* 43, 850–856
 54. Jamal, M. et al. (2018) Bacterial biofilm and associated infections. *J. Chin. Med. Assoc.* 81, 7–11
 55. Donlan, R.M. (2001) Biofilms and device-associated infections. *Emerg. Infect. Dis.* 7, 277–281
 56. Fux, C.A. et al. (2005) Survival strategies of infectious biofilms. *Trends Microbiol.* 13, 34–40
 57. Costerton, J.W. et al. (1999) Bacterial biofilms: a common cause of persistent infections. *Science* 284, 1318–1322
 58. Biesecker, S.G. et al. (2018) The functional amyloid curli protects *Escherichia coli* against complement-mediated bactericidal activity. *Biomolecules* 8, E5
 59. Jonas, K. et al. (2007) Roles of curli, cellulose and BapA in *Salmonella* biofilm morphology studied by atomic force microscopy. *BMC Microbiol.* 7, 70
 60. Larsen, P. et al. (2008) Amyloid-like adhesins produced by floc-forming and filamentous bacteria in activated sludge. *Appl. Environ. Microbiol.* 74, 1517–1526
 61. Latasa, C. et al. (2005) BapA, a large secreted protein required for biofilm formation and host colonization of *Salmonella enterica* serovar Enteritidis. *Mol. Microbiol.* 58, 1322–1339
 62. Peschel, A. and Otto, M. (2013) Phenol-soluble modulins and staphylococcal infection. *Nat. Rev. Microbiol.* 11, 667–673
 63. Tukul, C. et al. (2005) CsgA is a pathogen-associated molecular pattern of *Salmonella enterica* serotype Typhimurium that is recognized by Toll-like receptor 2. *Mol. Microbiol.* 58, 289–304
 64. Tukul, C. et al. (2009) Responses to amyloids of microbial and host origin are mediated through Toll-like receptor 2. *Cell Host Microbe* 6, 45–53
 65. Ather, J.L. et al. (2011) Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. *J. Immunol.* 187, 64–73
 66. Cheng, N. et al. (2008) Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. *J. Immunol.* 181, 22–26
 67. Liu, S. et al. (2012) TLR2 is a primary receptor for Alzheimer's amyloid beta peptide to trigger neuroinflammatory activation. *J. Immunol.* 188, 1098–1107
 68. Niemi, K. et al. (2011) Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. *J. Immunol.* 186, 6119–6128
 69. Thongsomboon, W. et al. (2018) Phosphoethanolamine cellulose: A naturally produced chemically modified cellulose. *Science* 359, 334–338
 70. Gallo, P.M. et al. (2015) Amyloid-DNA composites of bacterial biofilms stimulate autoimmunity. *Immunity* 42, 1171–1184
 71. Tursi, S.A. et al. (2017) Bacterial amyloid curli acts as a carrier for DNA to elicit an autoimmune response via TLR2 and TLR9. *PLoS Pathog.* 13, e1006315
 72. Petri, M. et al. (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum.* 64, 2677–2686
 73. Munroe, M.E. et al. (2016) Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. *Ann. Rheum. Dis.* 75, 2014–2021
 74. Zandman-Goddard, G. and Shoenfeld, Y. (2003) SLE and infections. *Clin. Rev. Allergy Immunol.* 25, 29–40
 75. Jung, J.Y. and Suh, C.H. (2017) Infection in systemic lupus erythematosus, similarities, and differences with lupus flare. *Korean J. Intern. Med.* 32, 429–438
 76. Wu, Y.W. et al. (2015) Toll-like receptors: potential targets for lupus treatment. *Acta Pharmacol. Sin.* 36, 1395–1407
 77. Celhar, T. et al. (2012) TLR7 and TLR9 in SLE: when sensing self goes wrong. *Immunol. Res.* 53, 58–77
 78. Shi, L. et al. (2014) The SLE transcriptome exhibits evidence of chronic endotoxin exposure and has widespread dysregulation of non-coding and coding RNAs. *PLoS One* 9, e93846
 79. Chughtai, B. et al. (2017) Is vaginal mesh a stimulus of autoimmune disease? *Am. J. Obstet. Gynecol.* 216, 495 e491–495 e497
 80. Chughtai, B. et al. (2017) Hernia repair with polypropylene mesh is not associated with an increased risk of autoimmune disease in adult men. *Hernia* 21, 637–642
 81. Clancy, C. et al. (2019) Polypropylene mesh and systemic side effects in inguinal hernia repair: current evidence. *Ir. J. Med. Sci.* Published online

March 27, 2019. <https://doi.org/10.1007/s11845-019-02008-5>.

82. Strietzel, F.P. et al. (2019) Implants in patients with oral manifestations of autoimmune or mucocutaneous diseases – A systematic review. *Med. Oral Patol. Oral Cir. Bucal*. 24, e217–e230
83. Kathju, S. et al. (2015) Direct demonstration of bacterial biofilms on prosthetic mesh after ventral herniorrhaphy. *Surg. Infect.* 16, 45–53
84. Langbach, O. et al. (2016) Oral, intestinal, and skin bacteria in ventral hernia mesh implants. *J. Oral Microbiol.* 8, 31854